Indiana Secures $16.5M from $720M Multi-State Opioid Settlement

Indiana is set to receive approximately $16.5 million as part of a $720 million national opioid settlement with eight pharmaceutical companies, including Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan (now part of Viatris), Sun, and Zydus. The settlement prohibits these companies from promoting opioids or opioid products, manufacturing or distributing products containing more than 40 mg of oxycodone per pill, offering discounts or rebates, and providing funding or lobbying related to opioids. Additionally, companies cannot incentivize employees financially based on opioid sales volume, and Indivior is barred from producing opioid products for the next decade. This latest settlement brings Indiana’s total opioid-related settlements to about $1.1 billion since Attorney General Todd Rokita took office in 2021. Rokita emphasized the settlements' role in holding companies accountable for their contributions to the opioid crisis that has claimed thousands of lives in the state. Some companies will make annual payments while others will pay their obligations in a single lump sum.